Taxotere or docetaxel
Use: Taxotere is a chemotherapy drug used to treat breast cancer, non-small cell lung cancer, head and neck cancer and prostate cancer.
Side Effects: Causes permanent, untreatable hair loss (alopecia) of the head, eyebrows, eyelids, under arms, and/or pubic areas.
Failure to Warn: Taxotere’s manufacturer, Sanofi-Aventis U.S. LLC, knew that Taxotere caused 6-10% of women to suffer permanent, untreatable hair loss but chose not to warn doctors and their patients of the risk. In 1998, Sanofi sponsored a study called GEICAM 9805 which revealed that 9.2 percent of women who used Taxotere suffered permanent hair loss. In 2006, Dr. Scot Sedlacek of the Rocky Mountain Cancer Centers conducted a study that showed Taxotere caused more than 6 percent of women to sustain permanent hair loss. Had cancer patients known that Taxotere was not any more effective than other chemotherapy drugs, cancer patients would have elected to use the other chemotherapy drugs that did not cause permanent hair loss. Before losing patent protection in 2009, Taxotere made over $3 billion for Sanofi.
Lawsuit: There are currently more than 8,700 Taxotere lawsuits filed. The Multi-District Litigation is located in the United States District Court East District of Louisiana.
Trial dates: There are currently four cases (Bellwether trials) scheduled for trial in January 28, 2019, April 8, 2019, July 15, 2019 and November 4, 2019.
Do you qualify? You may be eligible for compensation if:
- You are a woman who was diagnosed with breast cancer, head or neck cancer, or non-small cell lung cancer.
- You stopped taking Taxotere six or more months ago.
- You suffer from total or partial baldness.
We can help: If you or someone you know have experienced permanent hair loss after using Taxotere, call us today at 281-286-9100 for a free consultation.